Drs Rapuano and Nagra of Wills Eye Hospital discuss the FDA Approval of Xiidra
Christopher J. Rapuano, MD, Chief of The Wills Eye Hospital Cornea Service and Parveen K. Nagra, MD, Wills Eye Cornea Service Staff comment on the FDA Approval of Xiidra for the treatment of signs and symptoms of dry eye disease.
The U.S. Food and Drug Administration approved Xiidra (lifitegrast ophthalmic solution) for the treatment of signs and symptoms of dry eye disease, on Monday, July 11, 2016. Xiidra is the first medication in a new class of drugs, called lymphocyte function-associated antigen 1 (LFA-1) antagonist, approved by the FDA for dry eye disease.
Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency. The chance of experiencing dry eye increases with age, affecting approximately five percent of the adult population age 30-40 and 10 to 15 percent of adults over age 65, and is more common among women. When severe and left untreated, this condition can lead to pain, ulcers or scars on the part of the eye called the cornea. Dry eye can make it more difficult to perform some activities, such as using a computer or reading for an extended period of time, and it can decrease tolerance for dry environments, such as the air inside an airplane.
Wills Eye Hospital is a leader in the treatment of dry eye disease. We treat patients for dry eye disease here in Philadelphia, New Jersey and Delaware. Wills Eye doctors have been a part of the research and patients studies that are key for finding a treatment for dry eye disease.
Смотрите видео Drs Rapuano and Nagra of Wills Eye Hospital discuss the FDA Approval of Xiidra онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь Wills Eye Hospital 14 Июль 2016, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 5,290 раз и оно понравилось 19 людям.